Literature DB >> 9395870

Indications for penetrating keratoplasty and associated procedures, 1989-1995.

N Lois1, V O Kowal, E J Cohen, C J Rapuano, J A Gault, I M Raber, P R Laibson.   

Abstract

PURPOSE: To identify changing trends in indications for penetrating keratoplasty and associated surgical procedures.
METHODS: Review of charts from all patients who underwent penetrating keratoplasty at Wills Eye Hospital from January 1, 1989 through December 31, 1995.
RESULTS: A total of 2,442 corneal transplants were performed in 2,186 patients. The leading indication for penetrating keratoplasty was pseudophakic corneal edema, accounting for 634 cases (26.0%); 54.7% of them were associated with anterior chamber intraocular lenses, 36.4% with posterior chamber intraocular lenses, and 3.1% with iris-fixated intraocular lenses. Regraft (17.8%), Fuchs' dystrophy (15.7%), and keratoconus (13.2%) followed pseudophakic corneal edema in frequency. Cataract extraction, with or without intraocular lens implantation, was combined with penetrating keratoplasty in 439 cases of 1,264 phakic eyes (34.7%). Intraocular lens exchange was performed in 285 of the 634 cases of pseudophakic corneal edema (44.9%).
CONCLUSION: Pseudophakic corneal edema was the leading indication for penetrating keratoplasty, with an increasing number of cases associated with posterior chamber intraocular lenses during the study period (p = 0.001). The number of regrafts steadily increased between 1989 and 1995 (p = 0.001), being the second most common indication for corneal transplantation since 1992.

Entities:  

Mesh:

Year:  1997        PMID: 9395870

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  18 in total

1.  Epidemiology and molecular analysis of herpes simplex keratitis requiring primary penetrating keratoplasty.

Authors:  B C Branco; P A Gaudio; T P Margolis
Journal:  Br J Ophthalmol       Date:  2004-10       Impact factor: 4.638

Review 2.  Trends in penetrating keratoplasty in the United States 1980-2005.

Authors:  Faris R Ghosheh; Federico A Cremona; Christopher J Rapuano; Elisabeth J Cohen; Brandon D Ayres; Kristin M Hammersmith; Irving M Raber; Peter R Laibson
Journal:  Int Ophthalmol       Date:  2008-06       Impact factor: 2.031

3.  Repeat penetrating keratoplasty: indications, graft survival, and visual outcome.

Authors:  H Al-Mezaine; M D Wagoner
Journal:  Br J Ophthalmol       Date:  2006-03       Impact factor: 4.638

4.  Longitudinal study of keratoconus progression.

Authors:  Xiaohui Li; Huiying Yang; Yaron S Rabinowitz
Journal:  Exp Eye Res       Date:  2007-07-06       Impact factor: 3.467

5.  Visual outcome in corneal grafts: a preliminary analysis of the Swedish Corneal Transplant Register.

Authors:  M Claesson; W J Armitage; P Fagerholm; U Stenevi
Journal:  Br J Ophthalmol       Date:  2002-02       Impact factor: 4.638

6.  Fuchs' corneal dystrophy.

Authors:  Allen O Eghrari; John D Gottsch
Journal:  Expert Rev Ophthalmol       Date:  2010-04

7.  Trends in Corneal Transplantation in Keratoconus.

Authors:  Daniel Sarezky; Stephen E Orlin; Wei Pan; Brian L VanderBeek
Journal:  Cornea       Date:  2017-02       Impact factor: 2.651

8.  Endothelial cell microRNA expression in human late-onset Fuchs' dystrophy.

Authors:  Mario Matthaei; Jianfei Hu; Laura Kallay; Charles G Eberhart; Claus Cursiefen; Jiang Qian; Eva-Maria Lackner; Albert S Jun
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-01-09       Impact factor: 4.799

9.  Endothelial cell whole genome expression analysis in a mouse model of early-onset Fuchs' endothelial corneal dystrophy.

Authors:  Mario Matthaei; Jianfei Hu; Huan Meng; Eva-Maria Lackner; Charles G Eberhart; Jiang Qian; Haiping Hao; Albert S Jun
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-03-15       Impact factor: 4.799

Review 10.  [Triple surgery. Keratoplasty combined with cataract extraction and intraocular lens implantation].

Authors:  E M Messmer; S Dotse; A Müller; A Kampik
Journal:  Ophthalmologe       Date:  2004-06       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.